All (5)News (5)Transcripts (0)Press Releases (0)

News60 days ago

Soligenix Stock Dips Amid $7.5 Million Public Offering

Soligenix shares are trading lower after the company announced the pricing of a $7.5 million public offering, which may dilute existing shareholders.

News63 days ago

Soligenix Shares Rise with Strategic Advisor Appointment

Soligenix shares are trading higher after the company announced the appointment of former White House Economic Adviser Tomas J. Philipson, PhD as a Strategic Advisor, enhancing the company's strategic initiatives as they advance their product candidate HyBryte™ in a Phase 3 clinical trial.

News98 days ago

Soligenix Shares Rise on FDA Orphan Drug Designation

Soligenix shares are trading higher after the FDA granted orphan drug designation to its drug SGX945 for the treatment of Behçet's Disease, offering market exclusivity and various regulatory benefits.

News116 days ago

Soligenix Shares Climb on Positive Phase 2 Trial Results

Soligenix shares are trading higher after the company announced successful completion of its Phase 2a trial, demonstrating biological efficacy of SGX945 for treating Behçet's Disease.

News146 days ago

Soligenix Boosts Manufacturing Capabilities with U.S. Transfer

Soligenix shares are trading higher after the company successfully completed the U.S. transfer of the manufacturing process for its synthetic hypericin, enhancing commercial production for treatments like HyBryte™ and SGX302.